By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



650 E Kendall Street

Cambridge  Massachusetts    U.S.A.
Phone: n/a Fax: n/a


Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.




CEO: Ludwig Hantson

CFO: Robert Hombach

CSO (Scientific): John Orloff


Please click here for Baxalta job opportunitites.


Please click here for clinical trial information.

All Products


Key Statistics

Ownership: Public

Web Site: Baxalta
Employees: 16,000
Symbol: BXLT


Company News
Merck & Co. (MRK) Buys Former Baxalta (BXLT) Plant From Shire (SHPG) 8/7/2017 6:21:55 AM
With Baxalta (BXLT) Boosting Rare Drugs, Shire (SHPG) May Spin Off ADHD Drugs Business 8/3/2017 7:26:48 AM
New Alexion (ALXN) CEO Brings Two Former Baxalta (BXLT) Pals and One Pfizer (PFE) Alum Into the C-Suite 6/2/2017 5:45:41 AM
Former Baxalta (BXLT) CEO to Helm Struggling Alexion (ALXN) 3/27/2017 5:39:24 AM
In 3Q Report, Shire (SHPG) Breaks Out Data From Baxalta (BXLT) Acquisition and Announces Several Program Terminations 11/1/2016 6:09:03 AM
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT) 10/24/2016 5:52:16 AM
Editas Medicine (EDIT) Brings on New Execs From Sanofi Genzyme (SNY), Novartis AG (NVS), Baxalta (BXLT) and Bristol-Myers Squibb (BMY) 10/5/2016 7:19:35 AM
Shire (SHPG) Terminates a Couple of Biosimilar Deals Made by Baxalta (BXLT) 9/27/2016 6:35:57 AM
SEC Filing Reveals Shire (SHPG) is Ready to Punt $172 Million Baxalta (BXLT) Deal With CTI BioPharma 9/20/2016 6:43:25 AM
Acadia (ACAD) Scores Former Baxalta (BXLT) Exec as New CFO 8/24/2016 7:10:00 AM